Acura Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Acura Pharmaceuticals Inc (ACUR) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Acura Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs -M combined for its competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-90.8% annualized vs trailing 12 months).
- Peer revenue share: Acura Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ACUR Sales vs. its Competitors, Q4 2021
Acura Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
API endpoints for this dataset
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs -95.0% for Acura Pharmaceuticals Inc. Acura Pharmaceuticals Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.